Search

Your search keyword '"Dutt-Singkh Y"' showing total 10 results
Start Over Author "Dutt-Singkh Y"
10 results on '"Dutt-Singkh Y"'

1. 370 Genetically corrected autologous keratinocyte epidermal grafts improve wound healing and patient reported outcomes in patients with recessive dystrophic epidermolysis bullosa

Author

Eichstadt, S., primary, Barriga, M., additional, Teng, C., additional, Nguyen, N.T., additional, Gorell, E., additional, Siprashvili, Z., additional, Loutit, K., additional, Dutt-Singkh, Y., additional, Nazaroff, J., additional, Marinkovich, M.P., additional, and Tang, J., additional

Published
2019
Full Text
View/download PDF

7. 519 Phase I/IIa clinical trial for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes

Author

Siprashvili, Z., primary, Nguyen, N., additional, Gorell, E., additional, Loutit, K., additional, Dutt-Singkh, Y., additional, Nazaroff, J., additional, Khuu, P., additional, Furukawa, L., additional, Lorenz, H., additional, Leung, T., additional, Keene, D., additional, Rieger, K., additional, Khavari, P.A., additional, Lane, A., additional, Tang, J.Y., additional, and Marinkovich, M., additional

Published
2017
Full Text
View/download PDF

9. Validity and accuracy of a mobile phone application for the assessment of wounds in recessive dystrophic epidermolysis bullosa.

Author

Nazaroff J, Solis D, Barriga M, Dutt-Singkh Y, Li S, Marinkovich PM, and Tang JY

Subjects
Adolescent, Adult, Child, Epidermolysis Bullosa Dystrophica complications, Female, Humans, Male, Reproducibility of Results, Skin Ulcer etiology, Young Adult, Cell Phone, Epidermolysis Bullosa Dystrophica pathology, Mobile Applications, Skin Ulcer pathology
Published
2021
Full Text
View/download PDF

10. Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trial.

Author

Chiou AS, Choi S, Barriga M, Dutt-Singkh Y, Solis DC, Nazaroff J, Bailey-Healy I, Li S, Shu K, Joing M, Kwon P, and Tang JY

Subjects
Adolescent, Adult, Double-Blind Method, Epidermolysis Bullosa complications, Female, Humans, Male, Middle Aged, Pruritus etiology, Young Adult, Neurokinin-1 Receptor Antagonists therapeutic use, Pruritus drug therapy
Abstract

Background: Chronic pruritus causes major morbidity in epidermolysis bullosa (EB). The substance P-neurokinin 1 receptor (SP-NK1) pathway is a promising target for treating EB-related pruritus., Objective: To evaluate the safety and efficacy of the oral NK1 receptor antagonist serlopitant in treating moderate-severe pruritus in EB., Methods: The study randomized 14 patients to serlopitant or placebo for 8 weeks, followed by a 4-week washout and optional open-label extension. The primary end point was change in itch as measured by the Numeric Rating Scale. Secondary end points were change in itch during dressing changes and wound size., Results: We observed greater itch reduction with serlopitant, equivalent to a 0.64-point comparative reduction on the 11-point Numeric Rating Scale by week 8, although this failed to meet statistical significance (P = .11). More serlopitant patients achieved ≥3-point reduction compared with placebo (43% vs 14%, P = .35). In post hoc analysis excluding 1 patient with a concurrent seborrheic dermatitis flare, serlopitant achieved significantly greater median itch reduction from baseline by week 4 (-2 points vs 0, P = .01). We observed no statistically significant differences in secondary end points. Serlopitant was well-tolerated., Limitations: Small sample size due to disease rarity., Conclusion: The potential itch reduction with serlopitant observed in this trial will be pursued by a larger powered trial (NCT03836001)., (Copyright © 2019 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results